GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-01-26
- Last Posted Date
- 2015-01-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT00282347
A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate
- First Posted Date
- 2006-01-26
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT00282308
- Locations
- 🇺🇸
Evanston Northwestern Healthcare, Evanston, Illinois, United States
🇺🇸Borgess Research Institute, Kalamazoo, Michigan, United States
🇺🇸Justus Fiechtner MD - PP, Lansing, Michigan, United States
A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2013-07-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 684
- Registration Number
- NCT00281697
A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma
- First Posted Date
- 2006-01-06
- Last Posted Date
- 2009-03-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT00272415
A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-12-16
- Last Posted Date
- 2013-10-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 559
- Registration Number
- NCT00266227
A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2013-12-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1237
- Registration Number
- NCT00262067
A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-11-23
- Last Posted Date
- 2016-04-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1145
- Registration Number
- NCT00257608
- Locations
- 🇺🇸
Siouxland Hem-Onc Assoc LLP, Sioux City, Iowa, United States
🇺🇸Montana Cancer Specialists, Missoula, Montana, United States
🇺🇸Coastal Bend Cancer Center, Corpus Christi, Texas, United States
A Study of Xolair to Evaluate Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma
Completed
- Conditions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 8023
- Registration Number
- NCT00252135
A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2014-03-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 5000
- Registration Number
- NCT00251459
A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-24
- Last Posted Date
- 2011-10-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT00243412
© Copyright 2024. All Rights Reserved by MedPath